Home › Funds › Paradigm Biocapital Advisors LP › ASMB
Paradigm Biocapital Advisors LP position in ASMB
ASSEMBLY BIOSCIENCES INC · Health Care
Paradigm Biocapital Advisors LP reported holding 1,553,748 shares of ASMB (ASSEMBLY BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$36.5M, representing 0.73% of its reported portfolio and ranking #21 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed ASMB holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's ASMB position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in ASMB in Q4 2025 at 665,251 shares (US$22.6M). The position peaked in Q2 2026 at 1,553,748 shares, worth US$42.7M. Across 4 filings, Paradigm Biocapital Advisors LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,553,748 shares valued at US$36.5M. Notable position changes include a 134% increase in Q2 2026 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 665.25K | $22.63M | New |
| Q1 2026 | 665.25K | $18.46M | Hold |
| Q2 2026 | 1.55M | $42.70M | Add |
| Q3 2026 | 1.55M | $36.50M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ASMB and 13F data
ASMB (ASSEMBLY BIOSCIENCES INC) is a Health Care company. 55 other funds we track also report a position in ASMB — the largest reported positions include GILEAD SCIENCES, INC. (US$116.9M), Farallon Capital Management (US$44.1M), Commodore Capital LP (US$38.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ASMB
- GILEAD SCIENCES, INC. 4.98M sh · $116.91M · Q3 2026
- Farallon Capital Management 1.60M sh · $44.09M · Q2 2026
- Commodore Capital LP 1.42M sh · $38.88M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 1.60M sh · $37.69M · Q3 2026
- Parkman Healthcare Partners LLC 796.26K sh · $18.70M · Q3 2026
- Seven Fleet Capital Management LP 433.15K sh · $11.90M · Q2 2026
- DV EQUITIES, LLC 226.41K sh · $6.22M · Q2 2026
- Squadron Capital Management LLC 160.00K sh · $4.40M · Q2 2026
- B Group, Inc. 175.71K sh · $4.13M · Q3 2026
- Ally Bridge Group (NY) LLC 140.00K sh · $3.85M · Q2 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held ASMB?
Paradigm Biocapital Advisors LP has disclosed ASMB holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Paradigm Biocapital Advisors LP's current position in ASMB?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 1.55M shares of ASMB (ASSEMBLY BIOSCIENCES INC), valued at $36.50M, representing 0.73% of its reported portfolio and ranking #21.
Has Paradigm Biocapital Advisors LP been buying or selling ASMB?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP held unchanged its position in ASMB. The position peaked in Q2 2026 at 1.55M shares.
Which other funds hold ASMB?
Other major institutional holders of ASMB include GILEAD SCIENCES, INC., Farallon Capital Management, Commodore Capital LP, among 55 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.